Find Academic Supervisors

Joel Weadge is an Associate Professor in the Biology Department at Wilfrid Laurier University , Waterloo, Ontario. His research focuses on bacterial biofilms, glycobiology, and protein structure-function relationships. Contact: jweadge@wlu.ca , Office: BA425 (Bricker Academic). Education: PhD in Microbiology (University of Guelph, 2006) BSc (Hons) in Microbiology (University of Guelph, 2000) Research Interests center on bacterial biofilms as virulence factors in pathogens like E. coli and Salmonella . Key areas include: Structural and functional characterization of biofilm proteins (cellulose, curli fimbriae) Enzymology of carbohydrate modifications (acetylation, phosphoethanolamine transfer) Developing therapeutics targeting biofilm synthesis Biopolymer applications for medical/industrial use Publications highlight studies on Pseudomonas and Salmonella biofilm mechanisms, glycosyltransferases, and carbohydrate-active enzymes, with methodologies spanning X-ray crystallography to high-throughput biofilm profiling. Labs and Teams: The Weadge Lab investigates biofilm roles in food/water security and oral health, utilizing enzymology, mass spectrometry, and structural biology. Current members include graduate students, technicians, and research assistants.

• Bacterial Biofilms
• Bacterial Carbohydrates
• Protein Structure and Function
• +7 more

Joshua D. Rabinowitz is a Professor of Chemistry and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where he also serves as Director of the Ludwig Princeton Branch. His research focuses on achieving a quantitative, comprehensive understanding of cellular metabolism, with applications in both basic science and medical research. Dr. Rabinowitz's research interests span multiple areas of metabolism and systems biology: Quantitative analysis of metabolic networks and regulation Metabolomics and measurement of metabolite concentrations and fluxes Cancer cell metabolism and therapeutic targeting Metabolic regulation in microbes (E. coli, Saccharomyces cerevisiae) Biofuel production (focusing on Clostridium acetobutylicum) Metabolic impact of pathogen infection (viral infection of human cells) His laboratory has developed innovative methods for measuring cellular metabolites using state-of-the-art mass spectrometry technology and approaches for quantitating metabolic fluxes through isotope-labeling data interpretation. Analysis of recent publications reveals a strong focus on NAD+ metabolism, cancer metabolism, metabolic adaptations in disease states, and the intersection of metabolism with immunology and neuroscience, particularly in areas like T cell metabolism, Alzheimer's disease, and cardiac function. Dr. Rabinowitz has received recognition as a Highly Cited Researcher by Web of Science, indicating significant impact in his field. He advises several graduate students and has mentored numerous alumni, including Michel I. Nofal, Edmundo Leiva III, and Sean Hackett. His research is supported by multiple programs including NIH NHGRI Training Program and QCB Graduate Program. The Rabinowitz Lab operates at the intersection of chemistry, biology, and computational science, with all projects involving a mix of biological experiments, metabolomics, and computation to achieve their goal of a holistic understanding of cellular metabolism.

• Cellular Metabolism
• Metabolomics
• Systems Biology
• +5 more

Dr. Angelika Rambold is a Group Leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, heading the Laboratory for Metabolic Organelle Networks in Immunology within the Department of Developmental Immunology. Previously affiliated with the University of Münster's Center for Molecular Biology of Inflammation (ZMBE) and Institute of Medical Biochemistry until January 2025, she investigates how intracellular organelle networks regulate immune cell function during inflammation, infection, and metabolic stress. Her research centers on dynamic interactions between mitochondria, lysosomes, lipid droplets, and autophagosomes during cellular adaptation to nutrient deprivation and pathogen challenge. Key interests include organelle communication mechanisms in immune cell activation, metabolic reprogramming in T cells and macrophages, and how defects in organelle networks drive primary immunodeficiencies like Chediak-Higashi syndrome. She employs advanced live-cell microscopy, super-resolution imaging, metabolomics, and single-cell transcriptomics to dissect these processes in primary immune cells and human disease models. Analysis of her publication record reveals consistent focus on mitochondrial dynamics as a central regulator of immune cell metabolism and fate determination. Landmark studies demonstrate TFEB-mediated itaconate synthesis for bacterial control in macrophages and coordinated organelle network responses during starvation, establishing critical links between organelle communication, immunometabolism, and disease pathogenesis across multiple immune cell types. Dr. Rambold serves as a supervisor in the Cells in Motion International Max Planck Research School (CiM-IMPRS) Graduate Programme, mentoring PhD students in interdisciplinary research. Her laboratory maintains active collaboration with the Center for Chronic Immunodeficiency (CCI) at the University of Freiburg to translate basic findings on organelle-mediated immune defects into clinical insights for patient-oriented research.

• Immunology
• Cell Biology
• Metabolism
• +3 more

Matthew W. Buczynski is an Assistant Professor at the School of Neuroscience , part of the College of Science at Virginia Tech . Holding a Ph.D. in Biochemistry from the University of California San Diego (2008) and postdoctoral training at The Scripps Research Institute (2009-2016), he joined Virginia Tech in August 2016 after completing his postdoctoral fellowship. Education: B.S. in Chemistry, University of Michigan , 2001 Ph.D. in Biochemistry, University of California San Diego , 2008 Postdoctoral Training, The Scripps Research Institute , 2009-2016 Dr. Buczynski’s research program focuses on identifying novel druggable targets for addiction and neurological disorders through mass spectrometry and behavioral pharmacology . His work integrates chemical biology , molecular pharmacology , and in vivo microdialysis to study molecular changes in the brain during chronic drug exposure. Key areas include nicotine dependence , ethanol withdrawal , and cross-talk between pain and addiction mechanisms. His recent publications highlight endocannabinoid system modulation , TRPV1/TRPA1 receptor activation in pain, and diacylglycerol lipase (DAGL) mechanisms in nicotine withdrawal. He employs both self-administration and forced exposure models to validate therapeutic targets. Prospective students can contact him directly through his lab’s website .

• Neuroscience
• Drug Addiction
• Pharmacology
• +3 more

Lonny R. Levin is a Professor of Pharmacology at Weill Cornell Medical College , where he has worked since 2009. Collaborating extensively with Dr. Jochen Buck, he pioneered research on bicarbonate-regulated soluble adenylyl cyclase (sAC) , a critical enzyme in cAMP signaling. Education : B.S. from Cornell University (1983), Ph.D. from State University of New York at Stony Brook (1989) His research focuses on: cAMP signaling microdomains in mammalian cells Mitochondrial metabolism and pH sensing Sperm capacitation and energy regulation Nonhormonal contraceptive development via sAC inhibition Recent publications (2025-2023) highlight: Structural insights into sAC activation Metabolic adaptations during sperm capacitation Emerging role in corneal endothelium signaling Drug discovery for on-demand male contraception Grants from NIH (NIAID, NICHD) support his work on: Intravaginal rings for dual HIV/herpes prevention and contraception Metabolic communication in reproductive systems Signalosome regulation in mitochondria He maintains collaborations with institutions like EMD Millipore Corporation and co-founded Sacyl Pharmaceuticals, Inc. , holding proprietary interests in sAC-related intellectual property.

• Biochemistry
• Cell Biology
• Pharmacology
• +5 more

Grant E. O'Keefe, M.D., M.P.H., serves as Professor of Surgery at the University of Washington School of Medicine and holds adjunct appointments in Neurological Surgery, Orthopedics and Sports Medicine. Based at Harborview Medical Center in Seattle, he provides surgical and intensive care services for emergency and complex gastrointestinal conditions, emphasizing patient-centered decision-making in critical scenarios. His educational background includes: Medical Doctorate (M.D.) from University of Alberta Faculty of Medicine (1988) Master of Public Health (M.P.H.) from University of Washington General Surgery Residency at University of Alberta Faculty of Medicine General Surgery Fellowship at University of Washington Internship at Memorial University of Newfoundland Dr. O'Keefe's research focuses on trauma outcomes, critical care metabolism, and genetic determinants of sepsis recovery. He investigates nutritional interventions in critically ill patients, ventilator-associated complications, and biomarkers for predicting mortality in trauma cases. His work frequently employs metabolomics and genetic association studies to understand individual variations in treatment response. Analysis of his 2013-2018 publications reveals consistent emphasis on critical care and trauma, with studies examining respiratory failure duration, nutritional support efficacy, and genetic polymorphisms affecting sepsis outcomes. His research often utilizes large collaborative datasets from the NIH-funded Inflammation and Host Response to Injury program, highlighting translational approaches to improve trauma resuscitation and ICU management. Professional recognition includes: Fellow of the American College of Surgeons Board-certified in Surgery and Surgical Critical Care by the American Board of Surgery, Dr. O'Keefe has contributed significantly to the Inflammation and Host Response to Injury Collaborative Research Program, developing standard operating procedures for trauma nutrition and venous thromboembolism prophylaxis. While specific grant amounts aren't detailed, this multi-institutional NIH initiative represents substantial research funding. He mentors surgical trainees within UW's residency programs, though individual advisees aren't listed in available records. At Harborview Medical Center, Dr. O'Keefe operates within the General Surgery Clinic and surgical ICU, collaborating with multidisciplinary teams including trauma surgeons, critical care specialists, and nutrition support services. His clinical practice integrates research insights into trauma resuscitation protocols and complex abdominal surgery, with patient reviews highlighting both efficient communication and occasional concerns about bedside manner.

• General Surgery
• Trauma Surgery
• Critical Care Medicine
• +4 more

Prashant Mali is a Professor in the Department of Bioengineering at the University of California, San Diego . His research bridges genome engineering, RNA biology, and biomedical applications, with a focus on CRISPR-Cas systems and ADAR-mediated RNA editing. Education : Ph.D. in Bioengineering Key Affiliations : UC San Diego, Altman Clinical and Translational Research Institute Dr. Mali's work centers on CRISPR-Cas9 technology , RNA editing , and human pluripotent stem cells . His lab develops tools for programmable gene regulation, synthetic lethal screens, and metabolic pathway analysis in disease contexts. Recent publications highlight innovations in circular RNA engineering , ADAR activity mapping , and metabolic reprogramming in cancer . His team employs multi-omics approaches and in vivo models to translate genome editing into clinical applications. Students and Collaborators Current Lab Members : Sami Nourreddine (Postdoc), Amir Dailamy (Graduate), Andrew Portell (Graduate), Michael Tong (Graduate) Alumni : Kyle Ford (PhD 2022), Nathan Palmer (PhD 2022), Udit Parekh (PhD 2021) Research Themes CRISPR Screens : Synthetic lethal interactions, oncogenic pathways, metabolic vulnerabilities RNA Editing : ADAR engineering, circular guide RNAs, clinical translation Tissue Engineering : Vascularized organoids, cardiac maturation, ex vivo models

• Genome Engineering
• RNA Editing
• Stem Cell Research
• +4 more

Vignesh Ram Somnath is a Professor in the Biosciences of Sports at the University of Hildesheim since 2018. Previously, he served as an Acting Professor (2016-2018) and Research Associate (2010-2016) at the Institute of Sports Science, German Sports School Cologne. His work bridges molecular biology with sports science, focusing on skeletal muscle adaptation. Current: University Professor W2, University of Hildesheim 2016-2018: Acting Professor, University of Hildesheim 2010-2016: Research Associate, German Sports School Cologne 2005-2007: Research Assistant, German Sports School Cologne Research Interests: Regulation of molecular signaling pathways in skeletal muscle Mechanoprotective mechanisms during exercise Protein degradation dynamics Optimization of training and nutrition in competitive sports Integration of molecular biology with traditional sports science Key Publications (2020-2017) demonstrate expertise in: Metabolomics of muscle hypertrophy AMPK signaling in training Mitochondrial adaptations Extracellular vesicle analysis Calcium signaling pathways

• Sports Science
• Molecular Biology
• Exercise Physiology
• +3 more

Dr. Nika Danial is an Associate Professor of Cell Biology at Harvard Medical School and the Department of Cancer Biology at Dana-Farber Cancer Institute. She leads the Danial Lab, investigating metabolic mechanisms that regulate cellular adaptation to stress, with a focus on fuel utilization in health and disease. Dr. Danial holds additional roles as Co-Director of the NCI-funded T32 Training Program in Cancer Chemical Biology and Metabolism. Her research integrates biochemistry, mouse models, and metabolomics to study metabolic contributions to cancer, diabetes, and neurological disorders. Education: PhD from Columbia University (1999), postdoctoral training at Harvard Medical School and Dana-Farber under Dr. Stanley Korsmeyer. Key research areas include mitochondrial dynamics, glucose metabolism pathways, and the interplay between inflammation and metabolic signaling. The lab has pioneered studies on how metabolic flexibility impacts disease progression in pancreatic islets, lymphoma subtypes, and neuronal excitability. Publications highlight discoveries in mitochondrial fatty acid oxidation regulation, urea cycle anti-inflammatory mechanisms, and metabolic signatures in cancer subtypes. Her work has implications for developing therapies targeting metabolic vulnerabilities in diseases like diffuse large B-cell lymphoma and type 1 diabetes. The Danial Lab emphasizes rigorous training for the next generation of scientists through mentorship programs and interdisciplinary collaboration.

• Metabolic Biology
• Cancer Research
• Diabetes
• +4 more

Trond Vidar Hansen is a Professor at the Department of Pharmacy, University of Oslo , and leads the LIPCHEM research group . He collaborates with institutions including the University of Bergen and Vestlandets Innovasjonsselskap through the VITADEL project, which recently received NOK 5,000,000 in verification support from the Research Council of Norway. His research focuses on the synthesis and biological evaluation of specialized pro-resolving lipid mediators derived from omega-3 fatty acids, with applications in inflammation resolution, neuroinflammation, and drug development. University : University of Oslo Department : Department of Pharmacy Research Group : LIPCHEM Collaborations : University of Bergen, Vestlandets Innovasjonsselskap Research Interests : H Hansen's work centers on the organic synthesis of bioactive lipid derivatives, particularly pro-resolving mediators from omega-3 polyunsaturated fatty acids. His team investigates their roles in inflammatory disease models , neuroinflammation , and PPAR receptor activation , aiming to develop therapeutic agents for conditions like chronic pain, diabetes, and neurodegenerative disorders. The research integrates stereoselective chemistry , biochemical profiling , and pharmacological evaluation to validate these mediators' clinical potential. Recent Awards : 2025: NOK 2,000,000 verification support from Research Council of Norway 2025: Co-leader of NOK 5,000,000 VITADEL project Publications : His articles (2015–2024) reveal a focus on stereoselective synthesis of resolvins, protectins, and maresins, with applications in anti-inflammatory and neuroprotective therapies . Key subfields include omega-3 metabolite profiling , PPAR agonist design , and biosynthetic pathway elucidation , often utilizing human cell models and mouse disease models . Collaborative projects emphasize commercialization of academic research and translational medicine .

• Organic Chemistry
• Biochemistry
• Pharmacology
• +3 more

Professor Chris Greening is a Research Professor in the Department of Microbiology at Monash University, leading the One Health Microbiology group at the Biomedicine Discovery Institute. He holds a first-class degree in Molecular and Cellular Biochemistry from the University of Oxford (2010) and a PhD from the University of Otago (2013). His career includes postdoctoral roles at Otago, CSIRO, and the Australian National University, followed by appointments as a group leader in Monash’s School of Biological Sciences (2016) and a medically-focused NHMRC EL2 Fellow in the Department of Microbiology (2020). Research Focus: Bacterial persistence mechanisms, microbial metabolism, antimicrobial resistance (AMR), and One Health approaches linking environmental, clinical, and public health challenges. Awards: Fenner Medal (2022) and Jim Pittard Award (2019). Key Projects: RISE, Global Research Alliance on Agricultural GHGs, SAEF, and the ARC Carbon Utilisation Hub. Leads Monash’s AMR R&D Facility. Research spans metabolic pathways enabling bacterial survival in extreme conditions (e.g., hydrogen oxidation, F420 cofactor roles), climate impacts (greenhouse gas regulation), and translational programs addressing diarrheal diseases and AMR. Grants: ARC DECRA Fellowship, NHMRC EL2 Fellowship. Cross-disciplinary collaborations with engineers, ecologists, social scientists, and industry. Lab facilities include advanced microbiology, structural biology, and systems biology tools. Contributions align with UN SDGs: climate action (SDG13), good health (SDG3), and sustainable cities (SDG11).

• Microbial Metabolism
• Antimicrobial Resistance
• Environmental Microbiology
• +5 more

Prof. Om Parkash Dhankher is a distinguished Professor at the University of Massachusetts Amherst in the Stockbridge School of Agriculture. His research integrates plant biotechnology, phytoremediation, and climate-resilient crop development, focusing on detoxification of heavy metals, stress tolerance, and metabolic engineering for biofuels. He leads the Dhankher Lab , which pioneered transgenic plants for arsenic phytoremediation and manipulation of glutathione pathways. Education: Ph.D. in Plant Molecular Biology, Durham University (1998) M.Phil. in Biochemistry and Genetics, Kurukshetra University (1998) M.Sc. in Botany, Kurukshetra University (1987) B.Sc. in Medical, Maharishi Dayanand University (1985) Research interests include molecular mechanisms of abiotic stress tolerance, glutathione homeostasis for oxidative stress, arsenic-free crop engineering, and nanotechnology applications in agriculture. His work on sulfur nanoparticles has demonstrated reduced toxicity in rice and Brassica napus, while his Crambe abyssinica and Camelina sativa projects focus on biofuel yield enhancement. He pioneered the first transgenic plant combining arsC and γECS for arsenic remediation. Scientific leadership is reflected through editorial roles in Plant Cell Reports , Frontiers in Plant Sciences , and Environmental Pollution (among others). His accolades include fellowships from CSSA, ASA, ISEB, and ISPP, alongside US patents for metal-resistant plants and oil content engineering. Notably, his research on plant-based nickel extraction featured in the Wall Street Journal (2025) and was highlighted in Nature Biotechnology (2002), earning over $10M in research funding. Publications span 117 peer-reviewed articles and 4 books, including breakthroughs on arsenic detoxification , nanoparticle-plant interactions , and stress-associated proteins . His work has been featured in Science , Nature , PNAS , and ACS Nano , with recent 2025 articles on Camelina nickel tolerance and nanomaterial gene delivery . Collaborations span institutions in India, China, Italy, and Egypt through international outreach programs.

• Phytoremediation
• Plant Biotechnology
• Heavy Metal Toxicity Mitigation
• +3 more

Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.

• Tuberculosis
• Antibiotic Resistance
• Metabolomics
• +3 more

Pierre Maechler is a Professor at the University of Geneva's Faculty of Medicine in the Department of Cell Physiology and Metabolism. His research focuses on mitochondrial metabolism in pancreatic beta cells and its critical role in diabetes pathogenesis, with particular emphasis on glutamate dehydrogenase function and regulation. His laboratory investigates the molecular mechanisms of insulin secretion and beta-cell failure in Type 2 diabetes. Maechler's research interests span mitochondrial metabolism, energy homeostasis, and the molecular pathways linking nutrient sensing to insulin secretion. His work has established crucial connections between glutamate metabolism, beta-cell function, and diabetes development. He investigates how metabolic stressors like glucotoxicity and lipotoxicity impair beta-cell function through mitochondrial dysfunction. His research has expanded to include the role of glutamate dehydrogenase in multiple organs including brain, liver, and muscle, revealing systemic metabolic implications. Analysis of Maechler's publication record shows a sustained focus on beta-cell metabolism with evolving scope. Early work established fundamental mechanisms of glutamate signaling in insulin secretion, while recent publications demonstrate expansion into multi-organ metabolic regulation. His research has identified novel biomarkers for beta-cell mass, explored therapeutic targets for diabetes, and revealed unexpected roles for glutamate dehydrogenase in diverse physiological processes from muscle regeneration to brain function. The consistent thread through his work is understanding how mitochondrial metabolism governs cellular and systemic energy homeostasis. Professor Maechler has mentored numerous PhD students and postdoctoral fellows who have gone on to publish significant work in diabetes research. His laboratory collaborates extensively with clinical researchers to translate basic findings into potential therapeutic approaches for diabetes. Funding for his work likely comes from Swiss National Science Foundation and other European research agencies, supporting investigations into metabolic diseases. Maechler leads the Mitochondria and Energy Metabolism research group at the University of Geneva. His team employs a multidisciplinary approach combining molecular biology, metabolomics, and physiology to investigate metabolic regulation in health and disease. The laboratory maintains strong connections with clinical diabetes researchers, facilitating translational applications of their findings. Current work focuses on identifying novel therapeutic targets for preserving beta-cell function in diabetes.

• Mitochondrial metabolism
• Beta-cell function
• Diabetes research
• +5 more

Rosemary Davidson is a Lecturer in Nutrition and Biomedicine at Norwich Medical School, University of East Anglia. She is affiliated with multiple research centers including the Norwich Institute for Healthy Aging, Lifespan Health, Metabolic Health, and the Nutrition and Preventive Medicine research group. Education: PhD in Molecular Biology, University of East Anglia (2008) BSc (Hons) in Biomedical Sciences, Sheffield Hallam University (2004) Research Interests: Her research focuses on understanding the molecular mechanisms of joint tissue homeostasis and how dietary phytochemicals, particularly sulforaphane from broccoli, can promote musculoskeletal health and prevent diseases like osteoarthritis and Dupuytren’s disease. She employs a translational research approach, bridging laboratory findings with clinical intervention trials. Key areas include the role of sulforaphane in chondrocytes, high-throughput screening of bioactives, and targeting MMP-14 for therapeutic development. Recent Research Trends: Her most recent publications center on the genomic epidemiology of SARS-CoV-2, particularly during the pandemic, reflecting her critical role in establishing a clinical molecular diagnostics lab for Pillar 1 testing. These works highlight her expertise in public health genomics, transmission dynamics, and infection control strategies. Scientific Awards: Chancellor's Award for Outstanding Achievement (2021) Fahrenheit Placement Prize for Excellence (2004) Advising and Grants: Dr. Davidson is an active PhD supervisor and mentor in the EDESIA PhD program. She supervises undergraduate research projects in Biomedicine. Her funded research projects include studies on dietary bioactives in arthritis, metabolomics in arthritis (DeSignA study), and therapeutic targeting of MMP-14 in Dupuytren’s disease, supported by organizations such as Versus Arthritis, Orthopaedic Research UK, and The Kennedy Trust for Rheumatology Research. Labs and Teams: She is a key member of the Norwich Testing Initiative and collaborates extensively with the Norfolk and Norwich University Hospital Foundation Trust, Quadram Institute for Bioscience, Earlham Institute, and the COVID-19 Genomics UK Consortium. She also serves on the Norwich Research Park Biorepository Access Committee and UEA Human Tissue Committees.

• Nutrition & Preventive Medicine
• Biochemistry
• Healthy Aging
• +12 more